Chronic neutrophilic leukemia diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 12: Line 12:
{| class="wikitable"
{| class="wikitable"
|+
|+
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |World Health Organization (WHO) Criteria for CNL Diagnosis
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |[[World Health Organization]] (WHO) [[Criteria]] for CNL [[diagnosis]]
|-
|-
! style="background: #DCDCDC; text-align: center;" |1. Peripheral blood White blood cells(WBC) ≥25 × 109/L:
! style="background: #DCDCDC; text-align: center;" |1. [[Peripheral blood]] [[White blood cells]][[(WBC)]] ≥25 × 109/L:
| style="background: #F5F5F5;" |
| style="background: #F5F5F5;" |
* Segmented neutrophils plus band forms ≥80% of WBC
* Segmented neutrophils plus band forms ≥80% of WBC

Revision as of 20:52, 22 January 2019

Chronic neutrophilic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Chronic neutrophilic leukemia from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT scan

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic neutrophilic leukemia diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic neutrophilic leukemia diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic neutrophilic leukemia diagnostic study of choice

CDC on Chronic neutrophilic leukemia diagnostic study of choice

Chronic neutrophilic leukemia diagnostic study of choice in the news

Blogs on Chronic neutrophilic leukemia diagnostic study of choice

Directions to Hospitals Treating Chronic neutrophilic leukemia

Risk calculators and risk factors for Chronic neutrophilic leukemia diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

World health organization (WHO) introduces criteria for the diagnosis of chronic neutrophilic leukemia (CNL) that are based on the laboratory finding of peripheral blood cells, bone marrow, cytogenic mutation, and differential diagnosis.

Diagnostic Study of Choice

Study of choice

The diagnosis of CNL is based on the WHO criteria, which include:[1]

World Health Organization (WHO) Criteria for CNL diagnosis
1. Peripheral blood White blood cells(WBC) ≥25 × 109/L:
  • Segmented neutrophils plus band forms ≥80% of WBC
  • Neutrophil precursors <10% of WBC
  • Myeloblasts rarely observed
  • Monocyte count <1 × 109/L
  • No dysgranulopoies.
2. Hypercellular bone marrow:
  • Neutrophil granulocytes increased in percentage and number
  • Normal neutrophil maturation
  • Myeloblasts <5% of nucleated cells
3. Not meeting WHO criteria for:
  • BCR-ABL1+ chronic myeloid leukemia,
  • Polycythemia vera
  • Essential thrombocythemia,
  • Primary myelofibrosis
4.No rearrangement of:
  • PDGFRA,
  • PDGFRB,
  • FGFR1,
  • PCM1-JAK2
5.Presence of CSF3RT618I or other activating CSF3R mutation or

In the absence of a CSFR3R mutation, persistent neutrophilia (at least 3 months), splenomegaly, and no identifiable cause of reactive neutrophilia

including the absence of a plasma cell neoplasm or, if present, demonstration of clonality of myeloid cells by cytogenetic or molecular studies.

References

  1. Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.

Template:WH Template:WS